Motley FoolNOV 133 min read$RLMD

Relmada (RLMD) Q3 2025 Earnings Call Transcript

Image source: The Motley Fool.Thursday, November 13, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...

Original reporting

Motley Fool · Motley Fool Transcribing, https://www.facebook.com/themotleyfool/

Published Nov 13, 2025, 10:26 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 13, 2025, 11:30 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Source · www.fool.com

Decision brief

The 30-second read

$RLMDNeutralMed

Why it matters

Steady earnings suggest operational stability, but investors should watch for pipeline developments and regulatory updates.

Market read

The earnings call provides insights into the company's current financial health and growth prospects, relevant for biotech investors.

What to watch

Potential upcoming drug approvals or clinical trial results could significantly alter outlooks.

Timing: Immediate; news published within the last 24 hours.

Background

Relmada is a biotech company specializing in pain management therapies. The Q3 2025 earnings reflect ongoing clinical development and commercialization efforts.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$RLMDNeutralMedium confidence

Context

High relevance due to direct mention in earnings call transcript.

Expected impact

Moderate upward price movement expected over the next 1-2 weeks.

Evidence & confidence

The earnings call reflects steady performance without significant surprises, supporting a cautiously optimistic outlook.

Market effects

Sector

Potential positive sentiment in the Life Sciences sector due to stable earnings.

Regional

Limited regional impact; primarily US-focused earnings call.

Global

Moderate; reflects sector-wide trends but no major global shifts.

Counterpoint

What could challenge this read

The earnings call may be a temporary stabilization; longer-term risks include regulatory hurdles and competitive pressures.

Key entities

Company
Relmada Therapeutics
Biotech firm focused on pain management solutions.

Read at source ← All news

AUG 14

$RLMDMed

Relmada (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics (RLMD) reported Q2 2026 results and an execution update. Cash was $217.7M at June 30, 2026, funding operations through 2029. Net loss was $12.9M ($0.11/share). Management expects IND filings for NDV-01 and sepranolone by end-2026 and Phase 3 RESCUE enrollment to start after IND clearance.

fool.com6 min

AUG 6

$RLMDMed

RELMADA THERAPEUTICS, INC. (RLMD): Results of Operations and Financial Condition

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ● Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational

SEC EDGAR 8-K6 min

SEP 14

$PYPLMed

PayPal’s New CEO Bets on Going It Alone After $50B Buyout

PayPal CEO Dan Schulman aims to revamp the company's struggling businesses, launch new features, and cut costs. His plan includes transforming Venmo into a full money-management tool and improving the checkout button. Rival offers for PayPal, including one from Stripe and Advent International, fell through, and shares have since declined. Schulman's turnaround strategy also involves expanding Venmo's crypto trading and PYUSD stablecoin. According to the Wall Street Journal, some analysts remain

pymnts.com3 min

SEP 14

$CMGMed

2 Monster Stocks to Buy and Hold for at Least the Next 5 Years

Chipotle (CMG) expanded internationally via partnerships, opening in South Korea and Mexico. It plans further Asian expansion. Domestically, it relaunched rewards to combat softer sales. e.l.f. Beauty (ELF) launches rhode in Europe, targeting a large existing social media following. Both companies aim for long-term growth through international markets.

fool.com3 min

SEP 13

$PEPMed

Publicis wins PepsiCo global media business

Publicis Groupe won PepsiCo’s global media business, consolidating strategy and technology under a new 'One PepsiCo' structure. PepsiCo spent $5.4B on marketing in 2025, including $3.4B on advertising. Publicis may withdraw from Coca-Cola’s media review. PepsiCo aims to modernize media operations with AI and data.

reel360.com2 min